- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking…Endpoints · 27d ago↗ source
- Beeline adds $126M to Bain-backed immunology pipeline from Bristol MyersBristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team. Bain Capital, the Canada Pension Plan Investment Board, and Bristol…Endpoints · 27d ago↗ source
- BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma studyBeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. T…